September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Comparison of Two Treatments for Corneal Neovascularization One-Year Follow-Up: Photodynamic therapy with Verteporfin vs Photodynamic Therapy combined with Subconjunctival Ranibizumab.
Author Affiliations & Notes
  • ALEXANDRA PENA
    Ophthalmology, REGIONAL HOSPITAL LIC. ADOLFO LOPEZ MATEOS ISSSTE, MEXICO CITY, Mexico
  • Alejandro Navas
    Cataract and refractive surgery, Institute of Ophthalmology Conde de Valenciana, Mexico, Mexico
  • Enrique O Graue-Hernandez
    Cataract and refractive surgery, Institute of Ophthalmology Conde de Valenciana, Mexico, Mexico
  • Guillermo de Wit
    Cornea and refractive surgery, Association to prevent blindness in Mexico, Mexico, Mexico
  • Rodrigo Bolanos
    Cornea and refractive surgery, Association to prevent blindness in Mexico, Mexico, Mexico
    Ophthalmology, REGIONAL HOSPITAL LIC. ADOLFO LOPEZ MATEOS ISSSTE, MEXICO CITY, Mexico
  • Footnotes
    Commercial Relationships   ALEXANDRA PENA, None; Alejandro Navas, None; Enrique Graue-Hernandez, None; Guillermo de Wit, None; Rodrigo Bolanos, None
  • Footnotes
    Support  NA
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3530. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      ALEXANDRA PENA, Alejandro Navas, Enrique O Graue-Hernandez, Guillermo de Wit, Rodrigo Bolanos; Comparison of Two Treatments for Corneal Neovascularization One-Year Follow-Up: Photodynamic therapy with Verteporfin vs Photodynamic Therapy combined with Subconjunctival Ranibizumab.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3530.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the long-term effectiveness of combined therapy with photodynamic therapy with Verteporfin and subconjunctival Ranibizumab vs photodynamic therapy with Verteporfin alone for corneal neovascularization treatment

Methods : Twenty eyes of 20 patients with clinically stable corneal neovascularization (CNV) were randomized into two groups: one group received photodynamic therapy with verteporfin (6 mg/m2), and the other group received combined same-day treatment with photodynamic therapy with verteporfin (6 mg/m2) and a single subconjunctival dose of Ranibizumab (Lucentis; 0.5 mg/0.05 mL). Anterior segment photography (color and red-free) and fluorescein angiography were performed before treatment and during follow-up on months 2, 4, 6 and 12 after treatment. Image analysis was used to determine the area of CNV as a percentage of the total corneal area. Morphologic changes were assessed clinically by two investigators: best-corrected visual acuity, intraocular pressure, neovascular area and vessel caliber were estimated at each visit.

Results : In photodynamic therapy with Verteporfin group successful photothrombosis of CNV was obtained immediately after treatment in the ten patients. In five cases, partial vessel recanalization was observed after 6 weeks, and treatment was repeated, with complete regression of new vessels. In combined treatment group successful photothrombosis of corneal neovascularization was obtained immediately after treatment in the ten patients, regression of new vessels was observed after 6 weeks. Regression in all patients was verified by corneal fluorescein angiography. In all cases no relevant side effects were observed. The reduction of CNV was noticeably higher in the group treated with dual therapy, one year after treatment the effect was maintained without recurrent CNV with a statistically significant difference between the two groups (p<0.001)

Conclusions : To our knowledge, this is the first study to report the use of subconjunctival Ranibizumab in combined therapy and its long-term effects. Our results suggest that combined administration of PDT with Verteporfin and subconjunctival injection of Ranibizumab might be used safely and effectively to treat clinically stable CNV. This combined therapy showed higher efficacy than PDT with Verteporfin.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×